These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26861858)

  • 1. Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention: An Analysis of the Randomized ATOLL Trial.
    Liu Z; Silvain J; Kerneis M; Barthélémy O; Payot L; Choussat R; Sabouret P; Cohen M; Pollack CV; Goldstein P; Zeymer U; Huber K; Vicaut E; Collet JP; Montalescot G
    Angiology; 2017 Jan; 68(1):29-39. PubMed ID: 26861858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).
    Montalescot G; Ellis SG; de Belder MA; Janssens L; Katz O; Pluta W; Ecollan P; Tendera M; van Boven AJ; Widimsky P; Andersen HR; Betriu A; Armstrong P; Brodie BR; Herrmann HC; Neumann FJ; Effron MB; Lu J; Barnathan ES; Topol EJ;
    JACC Cardiovasc Interv; 2010 Feb; 3(2):203-12. PubMed ID: 20170878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
    Brieger D; Collet JP; Silvain J; Landivier A; Barthélémy O; Beygui F; Bellemain-Appaix A; Mercadier A; Choussat R; Vignolles N; Costagliola D; Montalescot G
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):182-90. PubMed ID: 20578166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
    Montalescot G; Zeymer U; Silvain J; Boulanger B; Cohen M; Goldstein P; Ecollan P; Combes X; Huber K; Pollack C; Bénezet JF; Stibbe O; Filippi E; Teiger E; Cayla G; Elhadad S; Adnet F; Chouihed T; Gallula S; Greffet A; Aout M; Collet JP; Vicaut E;
    Lancet; 2011 Aug; 378(9792):693-703. PubMed ID: 21856483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin.
    Silvain J; O'Connor SA; Yan Y; Kerneis M; Hauguel-Moreau M; Zeitouni M; Overtchouk P; Ankri A; Brugier D; Vicaut E; Ecollan P; Galier S; Collet JP; Montalescot G;
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):503-511. PubMed ID: 30144017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).
    Collet JP; Huber K; Cohen M; Zeymer U; Goldstein P; Pollack C; Silvain J; Henry P; Varenne O; Carrié D; Coste P; Angioi M; Le Breton H; Cayla G; Elhadad S; Teiger E; Filippi E; Aout M; Vicaut E; Montalescot G;
    Am J Cardiol; 2013 Nov; 112(9):1367-72. PubMed ID: 24012033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
    Ferguson JJ; Califf RM; Antman EM; Cohen M; Grines CL; Goodman S; Kereiakes DJ; Langer A; Mahaffey KW; Nessel CC; Armstrong PW; Avezum A; Aylward P; Becker RC; Biasucci L; Borzak S; Col J; Frey MJ; Fry E; Gulba DC; Guneri S; Gurfinkel E; Harrington R; Hochman JS; Kleiman NS; Leon MB; Lopez-Sendon JL; Pepine CJ; Ruzyllo W; Steinhubl SR; Teirstein PS; Toro-Figueroa L; White H;
    JAMA; 2004 Jul; 292(1):45-54. PubMed ID: 15238590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial.
    Montalescot G; Gallo R; White HD; Cohen M; Steg PG; Aylward PE; Bode C; Chiariello M; King SB; Harrington RA; Desmet WJ; Macaya C; Steinhubl SR;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1083-91. PubMed ID: 19926048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
    Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
    J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy.
    Bugiardini R; Dorobantu M; Vasiljevic Z; Kedev S; Knežević B; Miličić D; Calmac L; Trninic D; Daullxhiu I; Cenko E; Ricci B; Puddu PE; Manfrini O; Koller A; Badimon L;
    Atherosclerosis; 2015 Jul; 241(1):151-6. PubMed ID: 25988359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
    Auffret V; Leurent G; Boulmier D; Bedossa M; Zabalawi A; Hacot JP; Coudert I; Filippi E; Castellant P; Rialan A; Rouault G; Druelles P; Boulanger B; Treuil J; Avez B; Le Guellec M; Gilard M; Le Breton H
    Arch Cardiovasc Dis; 2016 Dec; 109(12):696-707. PubMed ID: 27818120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial.
    Pellaton C; Cayla G; Silvain J; Zeymer U; Cohen M; Goldstein P; Huber K; Pollack C; Kerneis M; Collet JP; Vicaut E; Montalescot G;
    Am Heart J; 2015 Oct; 170(4):778-86. PubMed ID: 26386802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
    Cohen M; Théroux P; Borzak S; Frey MJ; White HD; Van Mieghem W; Senatore F; Lis J; Mukherjee R; Harris K; Bigonzi F;
    Am Heart J; 2002 Sep; 144(3):470-7. PubMed ID: 12228784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents.
    Li YJ; Rha SW; Chen KY; Jin Z; Wang L; Ramasamy S; Poddar KL; Minami Y; Park JY; Choi CU; Oh DJ; Jeong MH;
    J Cardiol; 2012 Jan; 59(1):22-9. PubMed ID: 22079855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial.
    Lavi S; Cantor WJ; Casanova A; Tan MK; Yan AT; Džavík V; Fitchett D; Cohen EA; Borgundvaag B; Heffernan M; Ducas J; Goodman SG
    Am Heart J; 2012 Feb; 163(2):176-81.e2. PubMed ID: 22305834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
    Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
    Fox KA; Antman EM; Cohen M; Bigonzi F;
    Am J Cardiol; 2002 Sep; 90(5):477-82. PubMed ID: 12208405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous enoxaparin versus unfractionated heparin in unselected patients undergoing percutaneous coronary interventions: the Zurich enoxaparin versus unfractionated heparin in PCI study (ZEUS).
    Bertel O; Ramsay D; Wettstein T; Kurz DJ; Stettler I; Straumann E; Frielingsdorf J; Maurer D; Naegeli B
    EuroIntervention; 2010 Aug; 6(3):407-12. PubMed ID: 20884422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.